Jason R. Westin
贾森·韦斯汀
MD, MS
Associate Professor; Director, Lymphoma Clinical Research副教授；淋巴瘤临床研究主任
👥Biography 个人简介
Dr. Jason Westin is a prominent lymphoma specialist at MD Anderson, known for leading the ZUMA-12 trial evaluating frontline axi-cel CAR-T for high-risk DLBCL. His work also encompasses polatuzumab vedotin combinations and novel immunotherapy strategies for aggressive lymphomas.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Frontline CAR-T Therapy (ZUMA-12)
Led the ZUMA-12 trial, the first study to evaluate axi-cel CAR-T in the frontline setting for high-risk DLBCL, demonstrating high complete response rates and reshaping initial treatment strategy.
Representative Works 代表性著作
Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care in High-Risk Large B-Cell Lymphoma (ZUMA-12)
The Lancet (2022)
Phase 2 results of frontline axi-cel in high-risk DLBCL showing 78% complete response rate, supporting potential shift of CAR-T to first-line therapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Carl H. June
University of Pennsylvania
Michel Sadelain
Memorial Sloan Kettering Cancer Center
Crystal L. Mackall
Stanford University
Katy Rezvani
MD Anderson Cancer Center
关注 贾森·韦斯汀 的研究动态
Follow Jason R. Westin's research updates
留下邮箱，当我们发布与 Jason R. Westin（The University of Texas MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment